

Liju Zong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7860643/publications.pdf>

Version: 2024-02-01

27
papers

524
citations

566801

15
h-index

713013

21
g-index

28
all docs

28
docs citations

28
times ranked

438
citing authors

#	ARTICLE	IF	CITATIONS
1	VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 33-42.	2.0	63
2	Expression of the immune checkpoint VISTA in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1437-1446.	2.0	44
3	PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia. <i>Histopathology</i> , 2019, 75, 421-430.	1.6	43
4	Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1609-1617.	5.1	42
5	Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer. <i>Experimental Cell Research</i> , 2018, 371, 222-230.	1.2	30
6	Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets. <i>Journal of Cancer</i> , 2019, 10, 11-19.	1.2	30
7	<p>Cervical cancer in women aged 25 years or younger: a retrospective study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2051-2058.	0.9	20
8	High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal Cancer. <i>Journal of Immunotherapy</i> , 2021, 44, 22-28.	1.2	20
9	PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, 631-637.	0.6	20
10	Roles of B7-H3 in Cervical Cancer and Its Prognostic Value. <i>Journal of Cancer</i> , 2018, 9, 2612-2624.	1.2	19
11	The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery. <i>Gynecologic Oncology</i> , 2020, 156, 676-681.	0.6	19
12	Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2163-2175.	1.0	19
13	Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer. <i>Modern Pathology</i> , 2022, 35, 266-273.	2.9	19
14	Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017. <i>Cancer Medicine</i> , 2020, 9, 2590-2599.	1.3	16
15	Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	0.9	16
16	Diagnosis and Management of Mixed Gestational Trophoblastic Neoplasia: A Study of 16 Cases and a Review of the Literature. <i>Frontiers in Oncology</i> , 2019, 9, 1262.	1.3	13
17	Management and prognosis of patients with liver metastases from gestational trophoblastic neoplasia: a retrospective cohort study. <i>Cancer Management and Research</i> , 2018, Volume 10, 557-563.	0.9	11
18	Carcinoma of the lower female genital tract in patients with genitourinary malformations: a clinicopathologic analysis of 36 cases. <i>Journal of Cancer</i> , 2019, 10, 3054-3061.	1.2	11

#	ARTICLE	IF	CITATIONS
19	CD105 overexpression mediates drug-resistance in choriocarcinoma cells through BMP9/Smad pathway. <i>Journal of Cancer</i> , 2020, 11, 272-283.	1.2	11
20	Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	11
21	Operative and Oncological Outcomes Comparing Sentinel Node Mapping and Systematic Lymphadenectomy in Endometrial Cancer Staging: Meta-Analysis With Trial Sequential Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 580128.	1.3	10
22	Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4275-4283.	1.0	9
23	Oncological Outcomes and Safety of Ovarian Preservation for Early Stage Adenocarcinoma of Cervix: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 777.	1.3	8
24	Expression of B7 family checkpoint proteins in cervical cancer. <i>Modern Pathology</i> , 2022, 35, 786-793.	2.9	7
25	<p>Emerging Targets of Immunotherapy in Gynecologic Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11869-11882.	1.0	6
26	Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 193-201.	1.2	2
27	B7-H4 Expression in Precancerous Lesions of the Uterine Cervix. <i>BioMed Research International</i> , 2021, 2021, 1-7.	0.9	1